The tissue-dependent expression of IFNLR1, particularly in epithelial cells, raises an interesting question – will the selective specificity make IFNλ a better alternative for treating cancer patients with NSCLC and other cancer with epithelial origin? This evidence concerns the gene IFNLR1 and non-small cell lung carcinoma.